Lumida
/BFLY
⌘K
Butterfly Network Inc

Butterfly Network Inc

BFLY
$7.33USD↑+2.95%+0.21 today

MARKET CAP

2.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$1
$10

AI Summary

Stalk
TrimMedium

Price is in a Stage 3 distribution with a clear lower­ highs/lower­ lows sequence and declining short­ term EMAs. Medium­ term bias is bearish as price trades below the 9/20/50 EMAs without constructive bail­out patterns, while RSI is oversold but shows no exhaustion. The long­ term uptrend remains intact above the rising 200­ day SMA. Execution posture is to trim into relief rallies toward the EMA resistance cluster around the 9/20/50 EMAs.

  • ↑Q2 2026 revenue $32.6M, up 39% YoY.
  • ↑Embedded partnerships drove $10.8M revenue, +439% YoY.
  • ↓Negative earnings yield and weak profitability impede long-term viability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Butterfly Network, Inc. (NYSE: BFLY) is a leading player in the medical device sector, specializing in handheld ultrasound technology. With its innovative Butterfly IQ series, the company aims to democratize access to ultrasound imaging, focusing on point-of-care ultrasound (POCUS) applications across a variety of healthcare settings, including emergency care, primary care, and home and community environments. Its strategic move toward embedded semiconductor technology positions Butterfly to transform traditional ultrasound applications while enhancing patient outcomes through advanced imaging solutions.

Bull says

  • ↑Q2 2026 revenue $32.6M, up 39% YoY.
  • ↑Embedded partnerships drove $10.8M revenue, +439% YoY.
  • ↑First positive operating cash flow marks efficiency gains.
  • ↑FY26 guidance of $119–123M revenue shows macro resilience.
  • ↑Launching Compass AI to accelerate enterprise ultrasound adoption.
  • ↑High liquidity and momentum factors support price stability.

Bear says

  • ↓Negative earnings yield and weak profitability impede long-term viability.
  • ↓Short interest elevated, signaling market skepticism.
  • ↓Director sold 95.7% of shares, raising confidence concerns.
  • ↓LTM cash burn of $46M risks depleting cash reserves.
  • ↓Intense competition from GE, Philips, Siemens pressures market share.
  • ↓Negative balance sheet health increases financial distress risk.

Investment themes with BFLY

Medical Devices↓ -0.50%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-15-2026neutral

Transcript signals

Bull points

  • So we do believe it's highly probable that before the end of the year, Butterfly will have its first state signed up.
  • So for us getting into home care, instead of waiting 10 years for organizations to finally get it, that every nurse should have a probe and they should be doing this on site, by just stepping up and showing how immediately we can provide these types of clinical and financial benefits, it opens the eyes to those at-risk providers that this can be done.
  • Butterfly is very uniquely positioned with this because it allows us, it uses our cloud capabilities, it uses our AI capabilities, it uses our education capabilities, our hardware capabilities, and our systemic software capabilities in managing data. It takes the entire offering of Butterfly and it allows us to deploy it in a very powerful way.

Bear points

  • you know, we, you know, the original guidance had contemplated, you know, a continuing of the momentum that we felt at the end of the year.
  • That said, we had expected to be further along in closing larger deals for additional growth. Those opportunities are still very much active while the sales cycle is being lengthened.
  • That being said, we are currently working on commercial terms to bring the first state live before the end of the year.
Read full transcript analysis ›